The stock of Vertex Pharmaceuticals Incorporated (VRTX) has declined around 1.2% in the past three months, losing almost $3 billion of its market value. A key reason for the stock price dip was the loss recorded by the company in the second quarter due to costs related to the$4.9 billion acquisition of Alpine Immune Sciences, which closed in May.Vertex enjoys a dominant position in the cystic franchise (“CF”) market. Vertex’s CF sales continue to grow, driven by its triple therapy, Trikafta/Kaftrio. Vertex ...